Hansen’s group recently revealed the therapeutic potential of highly specific P2X7 allosteric antagonist PKT100 modulating pulmonary hypertension and right ventricle hypertrophy via suppression of maladaptive ATP/P2X7 axis-derived inflammasome and IL-1β production [227]. This evidence concerns the gene P2RX7 and pulmonary arterial hypertension.